+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Healthcare Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032- Product Image
Healthcare Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032- Product Image
Sale

Healthcare Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5456956
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Healthcare Contract Development & Manufacturing Organization Market is projected to reach USD 391.77 Billion in 2026. It is expected to continue growing at a CAGR of 9.23%, reaching USD 668.80 Billion by 2032.

Healthcare contract development and manufacturing organizations are becoming strategic infrastructure for pharmaceutical, biotechnology, cell and gene therapy, vaccine, and medical device companies. The sector is supported by measurable demand drivers, including patent expirations, biologics growth, complex sterile manufacturing needs, supply chain diversification, and continued regulatory emphasis on quality-by-design.

CDMOs now compete on more than capacity. Sponsors increasingly evaluate partners by FDA, EMA, MHRA, PMDA, and WHO-aligned compliance records; technology transfer discipline; data integrity; containment capability; cold-chain readiness; and the ability to scale from clinical batches to commercial supply without compromising current good manufacturing practice standards.

Transformative Shifts in the CDMO Landscape

The healthcare CDMO landscape is shifting from transactional outsourcing to integrated development, manufacturing, packaging, and lifecycle management partnerships. Demand is rising for sterile injectables, high-potency active pharmaceutical ingredients, biologics, biosimilars, mRNA platforms, and advanced therapy medicinal products, where technical barriers and regulatory scrutiny favor experienced operators.

At the same time, sponsors are redesigning supply networks after pandemic-era disruptions, inflationary pressure, energy cost volatility, and geopolitical risk exposure. Dual sourcing, regionalized manufacturing, validated backup capacity, and stronger supplier qualification have become board-level priorities, especially for essential medicines, critical APIs, and temperature-sensitive biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is reshaping CDMO value creation across formulation screening, process development, predictive maintenance, deviation analysis, visual inspection, demand forecasting, and regulatory documentation. The strongest use cases are emerging where AI is paired with validated data pipelines, electronic batch records, laboratory information management systems, manufacturing execution systems, and quality management systems.

Regulators have not lowered expectations for control, traceability, or human accountability. FDA, EMA, and ICH quality frameworks continue to require data integrity, explainability, risk management, and documented validation. For CDMOs, AI advantage depends on governed implementation, model monitoring, cybersecurity controls, and audit-ready documentation rather than experimental automation alone.

Key Regional Insights

Asia-Pacific is expanding as a development and manufacturing hub, led by China, India, Japan, South Korea, Singapore, and Australia, with strengths in APIs, generics, biologics, biosimilars, vaccines, and clinical trial supply. The region benefits from established active ingredient ecosystems, growing domestic healthcare demand, government-backed life sciences investment, and rising adoption of international GMP standards. North America remains a premium CDMO region because of FDA proximity, advanced biologics infrastructure, venture-backed biotechnology demand, strong intellectual property protection, and deep capabilities in sterile fill-finish, cell therapy, gene therapy, and complex drug-device combinations.

Europe benefits from EMA coordination, mature GMP systems, high-value sterile and biologics manufacturing, and strong specialty pharmaceutical clusters across Western and Central Europe. Latin America is gaining relevance through Brazil and Mexico, where regulated pharmaceutical production, public health procurement, and nearshoring dynamics support regional CDMO activity. The Middle East is investing in localization through Saudi Arabia and the UAE, with national strategies focused on medicine security, technology transfer, and domestic pharmaceutical production. Africa is at an earlier stage, supported by vaccine manufacturing initiatives, the African Medicines Agency, and AfCFTA-enabled regional integration designed to improve access, harmonize regulation, and reduce dependence on imported essential medicines.

Key Economic & Strategic Group Insights

ASEAN is strengthening its role in pharmaceutical packaging, clinical supply, and regional manufacturing, supported by Singapore's biomanufacturing base and growing healthcare demand across Indonesia, Thailand, Vietnam, Malaysia, and the Philippines. The group is also benefiting from regulatory cooperation efforts, expanding hospital networks, and demand for affordable generics and specialty medicines. The GCC is prioritizing medicine security and local production, particularly in Saudi Arabia and the UAE, where industrial policy, healthcare modernization, and procurement localization are encouraging pharmaceutical manufacturing partnerships.

The European Union remains a leading quality and regulatory reference market, supported by harmonized medicinal product oversight, advanced pharmacovigilance systems, and high GMP expectations. BRICS countries offer scale, API depth, vaccine experience, and fast-expanding healthcare consumption, with China and India particularly important to global pharmaceutical supply chains. G7 markets continue to dominate high-value innovation outsourcing because of advanced R&D ecosystems, mature regulators, and demand for complex biologics, sterile products, and advanced therapies. NATO economies add resilience considerations, as defense preparedness, secure supply chains, stockpiling policies, and essential medicine availability increasingly intersect with healthcare manufacturing strategy.

Key Country Insights

The United States leads demand for advanced CDMO services through biotechnology innovation, FDA-regulated commercialization, strong capital markets, and significant demand for biologics, sterile injectables, cell therapies, gene therapies, and complex generics. Canada supports biologics, vaccines, radiopharmaceuticals, and clinical-stage development through public investment in biomanufacturing resilience and a research-intensive life sciences base, while Mexico benefits from nearshoring, competitive manufacturing economics, and proximity to U.S. supply chains. Brazil anchors Latin American pharmaceutical manufacturing through ANVISA-regulated scale, domestic generic demand, vaccine capabilities, and a large public healthcare system.

The United Kingdom, Germany, France, Italy, and Spain remain important European CDMO markets, supported by MHRA and EMA-aligned quality expectations, skilled scientific workforces, and established pharmaceutical manufacturing clusters. Germany and France are especially strong in pharmaceuticals, specialty manufacturing, injectables, and bioprocessing, while Italy and Spain provide mature contract manufacturing, packaging, and finished-dose capabilities. Russia maintains domestic pharmaceutical production priorities driven by import substitution and medicine security policies, though sanctions and supply restrictions influence technology access and cross-border partnerships. China and India provide major API, generics, biosimilars, and biologics capacity, with China emphasizing integrated innovation and India retaining global strength in cost-efficient development and regulated generics. Japan emphasizes quality, specialty innovation, and PMDA-aligned compliance; South Korea is a global biologics manufacturing leader with strong biosimilar and bioprocessing capabilities; and Australia supports clinical trials, early development, vaccines, and Asia-Pacific regulatory bridging through strong healthcare infrastructure and internationally recognized research standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient, quality-led growth. Recommended actions include qualifying dual suppliers for critical materials, investing in sterile and biologics capacity, strengthening technology transfer governance, and aligning operations with ICH Q9(R1), Q10, Q12, Q13, and emerging AI-related regulatory expectations.

CDMOs should also build differentiated capabilities in high-potency manufacturing, aseptic processing, single-use bioprocessing, advanced analytics, serialization, cold-chain logistics, and sustainability reporting. Sponsors should select partners through risk-based scorecards that evaluate inspection history, data integrity, digital maturity, scalability, financial stability, cybersecurity posture, environmental controls, and demonstrated performance in comparable products.

Research Methodology

This executive summary is grounded in secondary research from publicly available regulatory, policy, scientific, and industry sources, including FDA, EMA, MHRA, WHO, ICH, OECD, national health agencies, public health procurement documents, inspection guidance, scientific publications, company filings, investor disclosures, and peer-reviewed literature. The analysis emphasizes verifiable structural indicators such as manufacturing capability, regulatory frameworks, inspection expectations, supply chain trends, therapeutic modality requirements, and documented policy priorities.

Insights are synthesized through a market-mapping approach that compares regions, strategic groups, and countries across demand drivers, compliance maturity, outsourcing intensity, technology adoption, manufacturing specialization, and supply resilience. The methodology avoids unsupported market-size, market-share, or forecasting claims and uses only evidence-based directional insights supported by identifiable public sources.

Conclusion

The healthcare CDMO market is entering a more strategic phase defined by technical complexity, quality expectations, regional diversification, and digital transformation. Sponsors are relying on CDMOs not only to reduce fixed manufacturing investment but also to access specialized expertise, accelerate development timelines, support regulatory readiness, and protect supply continuity.

The strongest CDMO performers will combine regulatory credibility, flexible capacity, AI-enabled process intelligence, robust quality systems, skilled technical teams, and global network resilience. As biologics, sterile products, advanced therapies, vaccines, high-potency compounds, and complex generics expand, trusted CDMO partnerships will remain essential to competitive healthcare manufacturing.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Healthcare Contract Development & Manufacturing Organization Market, by Service Offering
7.1. Introduction
7.2. Contract Development Services
7.2.1. Clinical Development
7.2.1.1. Clinical Trials Support
7.2.1.2. Regulatory Support
7.2.2. Preclinical Development
7.2.2.1. In Vitro & In Vivo Studies
7.2.2.2. Toxicology Studies
7.2.3. Process Development
7.3. Contract Manufacturing Services
7.3.1. API Manufacturing
7.3.2. Finished Dosage Form Manufacturing (FDF)
7.3.3. Medical Device Manufacturing
7.3.4. Packaging & Labeling
8. Healthcare Contract Development & Manufacturing Organization Market, by Molecule Type
8.1. Introduction
8.2. Large Molecules
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.2.3. Vaccines
8.3. Small Molecules
9. Healthcare Contract Development & Manufacturing Organization Market, by Dosage Form
9.1. Introduction
9.2. Liquid Dosage Forms
9.3. Semi-Solid Dosage Forms
9.4. Solid Dosage Forms
10. Healthcare Contract Development & Manufacturing Organization Market, by Application
10.1. Introduction
10.2. Generic Drugs
10.3. Medical Devices
10.4. Patented Drugs
11. Healthcare Contract Development & Manufacturing Organization Market, by Therapeutic Area
11.1. Introduction
11.2. Cardiology
11.3. Immunology
11.4. Infectious Disease
11.5. Metabolic Disorders
11.6. Neurology
11.7. Oncology
12. Healthcare Contract Development & Manufacturing Organization Market, by End User
12.1. Introduction
12.2. Academic & Research Institutions
12.3. Biotechnology Companies
12.4. Generic Drug Manufacturers
12.5. Medical Device Companies
12.6. Pharmaceutical Companies
12.6.1. Big Pharmaceutical Companies
12.6.2. Small & Medium-sized Pharmaceutical Companies
13. Healthcare Contract Development & Manufacturing Organization Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Healthcare Contract Development & Manufacturing Organization Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Healthcare Contract Development & Manufacturing Organization Market, by Country
15.1. United States
15.2. Germany
15.3. China
15.4. United Kingdom
15.5. India
15.6. Japan
15.7. Russia
15.8. Brazil
15.9. Canada
15.10. Italy
15.11. Mexico
15.12. France
15.13. Spain
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Baxter International, Inc.
17.2. Boehringer Ingelheim International GmbH
17.3. Cambrex Corporation
17.4. Catalent Inc.
17.5. Charles River Laboratories International, Inc.
17.6. Corden Pharma International GmbH
17.7. Curia Global, Inc.
17.8. Eurofins Scientific SE
17.9. EVER company group
17.10. Evonik Industries AG
17.11. FUJIFILM Diosynth Biotechnologies
17.12. Jabil, Inc.
17.13. Lonza Group AG
17.14. MedPharm Ltd.
17.15. Merck KGaA
17.16. NextPharma GmbH
17.17. Piramal Group
17.18. Porton Pharma Solutions Ltd
17.19. Recipharm AB
17.20. Samsung Biologics
17.21. Sanmina Corporation
17.22. Siegfried Holding AG
17.23. Siegfried-Group
17.24. Thermo Fisher Scientific, Inc.
17.25. WuXi AppTec
List of Figures
FIGURE 1. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CONTRACT DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CLINICAL TRIALS SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL REGULATORY SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PRECLINICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IN VITRO & IN VIVO STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL TOXICOLOGY STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CONTRACT MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL API MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL API MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL API MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL FINISHED DOSAGE FORM MANUFACTURING (FDF) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MEDICAL DEVICE MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PACKAGING & LABELING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PACKAGING & LABELING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PACKAGING & LABELING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LARGE MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LARGE MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LARGE MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL LIQUID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SEMI-SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL SOLID DOSAGE FORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MEDICAL DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MEDICAL DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL MEDICAL DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PATENTED DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PATENTED DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PATENTED DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GENERIC DRUG MANUFACTURERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL MEDICAL DEVICE COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL BIG PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 160. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 162. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 163. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 164. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 165. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 166. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 167. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 168. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 169. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 171. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 172. EUROPE HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 186. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 187. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 188. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 189. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 190. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 191. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 192. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 193. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 194. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 195. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 197. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 198. AFRICA HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 200. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 202. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 203. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 204. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 205. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 206. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 207. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 208. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 209. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 210. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 211. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. ASEAN HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 213. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 215. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 216. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 217. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 218. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 219. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 220. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 221. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 222. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 224. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. GCC HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 239. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 240. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 241. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 242. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 243. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 244. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 245. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 246. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 247. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 248. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 250. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. BRICS HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 252. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 253. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 254. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 255. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 256. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 257. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 258. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 259. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 260. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 261. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 263. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. G7 HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 265. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 266. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 267. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT DEVELOPMENT SERVICES, 2017-2032 (USD MILLION)
TABLE 268. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 269. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 270. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT MANUFACTURING SERVICES, 2017-2032 (USD MILLION)
TABLE 271. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 272. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE MOLECULES, 2017-2032 (USD MILLION)
TABLE 273. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 274. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 275. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 276. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. NATO HEALTHCARE CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2017-2032 (USD MILLION)
TABLE 278. GLOBAL

Companies Mentioned

  • Baxter International, Inc.
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent Inc.
  • Charles River Laboratories International, Inc.
  • Corden Pharma International GmbH
  • Curia Global, Inc.
  • Eurofins Scientific SE
  • EVER company group
  • Evonik Industries AG
  • FUJIFILM Diosynth Biotechnologies
  • Jabil, Inc.
  • Lonza Group AG
  • MedPharm Ltd.
  • Merck KGaA
  • NextPharma GmbH
  • Piramal Group
  • Porton Pharma Solutions Ltd
  • Recipharm AB
  • Samsung Biologics
  • Sanmina Corporation
  • Siegfried Holding AG
  • Siegfried-Group
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 391.77 Billion
Forecasted Market Value ( USD ) by 2032 $ 668.8 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Biologics Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032 - Product Image

Biologics Contract Development & Manufacturing Organization Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report - Product Image

Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report

  • Report
  • 117 Pages
  • Global
From
Antibody Contract Development and Manufacturing Organization - Global Strategic Business Report - Product Image

Antibody Contract Development and Manufacturing Organization - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Healthcare Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Service, Workflow, Therapeutic Area, End-use, and Region with Growth Forecasts, 2025-2033 - Product Image

Healthcare Contract Development and Manufacturing Organization Market Size, Share & Trends Analysis Report by Type, Product, Service, Workflow, Therapeutic Area, End-use, and Region with Growth Forecasts, 2025-2033

  • Report
  • 120 Pages
  • Global
From
Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook 2026-2034: Market Share, and Growth Analysis by Service Type, Molecule Type, Dosage Form, Therapeutic Area - Product Image

Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook 2026-2034: Market Share, and Growth Analysis by Service Type, Molecule Type, Dosage Form, Therapeutic Area

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.